Sumitomo Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides products for atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastrointestinal; and Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application; Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio Company Limited; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. It also has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.

Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. focuses on developing pharmaceutical products, regenerative medicine, and non-pharmaceutical solutions, with a priority on Psychiatry & Neurology and Oncology areas. The company aims to contribute to global healthcare.

msh id	COM:SUMITOMO-PHARMA
symbol	4.51K
name	Sumitomo Pharma Co., Ltd.
homepage url	https://www.sumitomo-pharma.com/index.html
country	JP
sector	Healthcare
industry	Drug Manufacturers - Specialty & Generic
market	STOCKS
employee count	4.98K
crunchbase url	-
linkedin url	-
founders	-

market cap	1.06B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.27
growth cost of revenue	0.14
growth depreciation and amortization	0.08
growth ebitda	-1.03
growth ebitda ratio	-1.03
growth eps	-
growth eps diluted	-
growth general and administrative expenses	0.5
growth gross profit	-0.07
growth gross profit ratio	-0.06

4506

COM:SUMITOMO-PHARMA

Sumitomo Pharma Co., Ltd.

Last Close

593.00

21/11 06:45

Market Cap

162.09B

Beta: -

Volume Today

4.68M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	3.21B
cost of revenue	3.21B
depreciation and amortization	246.19M
ebitda	798.37M
ebitda ratio	0.22
eps	0.66
eps diluted	0.66
operating expenses	2.2B
operating income	552.18M
operating income ratio	0.15

accounts receivables	328.81M
capital expenditure	-81.8M
cash at beginning of period	1.3B
cash at end of period	921.11M
inventory	635.7M
working capital ttm	-156.99B

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-